SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-222962
Filing Date
2024-09-20
Accepted
2024-09-20 16:50:27
Documents
13
Period of Report
2024-09-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K d844019d8k.htm   iXBRL 8-K 38961
  Complete submission text file 0001193125-24-222962.txt   165174

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fbrx-20240917.xsd EX-101.SCH 2860
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fbrx-20240917_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fbrx-20240917_pre.xml EX-101.PRE 11268
15 EXTRACTED XBRL INSTANCE DOCUMENT d844019d8k_htm.xml XML 3629
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Filer) CIK: 0001419041 (see all company filings)

IRS No.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38052 | Film No.: 241313943
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)